Le Lézard
Classified in: Health
Subject: FDA

True Health Launches Comprehensive Celiac Disease & Gluten Sensitivity Testing


FRISCO, Texas, Feb. 5, 2018 /PRNewswire/ -- Today, True Health announced that it is now offering comprehensive testing for celiac disease and gluten sensitivity. When medically necessary, this testing will provide clinicians useful diagnostics to determine the specific cause of symptoms reported as a gluten sensitivity.

Despite an increasing awareness of celiac disease, the Celiac Disease Foundation states that approximately 80% of individuals in the United States with celiac disease are undiagnosed. Gluten-related conditions, including celiac disease, wheat allergy, and non-celiac gluten sensitivity, may produce identical symptoms, making accurate diagnosis challenging and potentially causing unnecessary suffering among those who experience symptoms.

"Public awareness of gluten-related disorders is rising. Many patients self-initiate a gluten-free diet, which may be medically unnecessary, expensive, and could result in weight gain or nutritional deficiencies," says Bobbie Sutton, MD, PhD, Vice President and Laboratory Director at True Health. "Our tests provide clinicians with actionable results that help identify a patient's gluten-related sensitivity and help determine the appropriate next steps."

The True Health Celiac Disease and Gluten Sensitivity Profile incorporates seven FDA-approved specific wheat-based serologic markers that can differentiate wheat allergy, celiac disease, and non-celiac gluten sensitivity. Biomarkers included are available to order as individual tests, or as a comprehensive profile to help provide simultaneous diagnostic information about multiple conditions in a single blood draw. Results from True Health's comprehensive testing offer a gateway to additional clinical assessment and effective patient management.

"Patients with gluten-related disorders often suffer in silence," says Chris Grottenthaler, CEO of True Health. "Our aim is to provide the diagnostic insight that can help providers gain clarity about the specific cause of symptoms, allowing them to design a treatment plan that offers symptom relief and improved patient care."

Additional information about True Health's Celiac Disease & Gluten Sensitivity testing can be found at https://truehealthdiag.com/gluten.

About True Health

True Health Group is focused on transforming patient care through integrated diagnostics and healthcare services. True Health Diagnostics, a subsidiary, specializes in earlier-stage diagnosis and prevention of chronic disease, including cardiovascular, diabetes, cancer, genetic disorders, autoimmune disease, and more. True Health is headquartered in Frisco, Texas, with operations across the country. More information can be found at truehealthdiag.com.

Media Contact

Julia Martin
[email protected]
804.343.2718 ext. 2336

SOURCE True Health Diagnostics


These press releases may also interest you

at 05:45
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to  ResearchAndMarkets.com's offering. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution...

at 05:10
Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions. These devices could be anything from equipment that helps stimulate the nervous system to...

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...



News published on and distributed by: